Literature DB >> 11051251

Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas.

U Manne1, H L Weiss, W E Grizzle.   

Abstract

There is a need for new prognostic parameters that could add insights into the aggressiveness of tumors. Because the expression of two well-characterized mucin antigens, MUC1 and MUC2, in colorectal adenocarcinomas (CRCs) has been correlated with the aggressiveness of CRCs, we evaluated the prognostic value of the expression of MUC1 and MUC2 in CRCs collected from African-American and Caucasian patients. Expression of MUC1 and MUC2 was evaluated by immunohistochemistry in 166 archival CRC specimens collected from 58 African-American and 108 Caucasian patients that had been analyzed previously for nuclear accumulation of p53 (p53nac). Univariate Kaplan-Meier and multivariate Cox proportional hazards models were used to determine the prognostic significance of expression of MUC1 and MUC2 in these CRCs. MUC1 expression was more frequent in advanced stage CRCs, whereas MUC2 expression was higher in the mucinous type of CRCs. Although similar proportions of CRCs from African-Americans and Caucasians expressed MUC1 and MUC2, the MUC1 expression was found to be an indicator of high risk of death from CRC in Caucasians (hazard ratio, 2.03; P = 0.038) but not in African-Americans. Furthermore, Caucasians with CRCs exhibiting concomitant expression of MUC1 and p53nac demonstrated the lowest probability of overall survival (log rank test, P = 0.004). No prognostic value was found for MUC2 alone or in combination with p53nac in either group of patients. Expression of MUC1 in CRCs is a valuable indicator of poor prognosis in Caucasian patients. Additionally, combined evaluation of MUC1 and p53nac increases the ability to identify Caucasian patients with aggressive subtypes of CRC and may be useful in selecting or in developing novel therapeutic regimes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051251

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

Review 1.  The efficient operation of the surgical pathology gross room.

Authors:  W C Bell; E S Young; P E Billings; W E Grizzle
Journal:  Biotech Histochem       Date:  2008-04       Impact factor: 1.718

2.  Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.

Authors:  A Lugli; I Zlobec; K Baker; P Minoo; L Tornillo; L Terracciano; J R Jass
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

3.  Bax expression is a candidate prognostic and predictive marker of colorectal cancer.

Authors:  Venkat R Katkoori; Catalina Suarez-Cuervo; Chandrakumar Shanmugam; Nirag C Jhala; Tom Callens; Ludwine Messiaen; James Posey; Harvey L Bumpers; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location.

Authors:  So Yeon Park; Hye Seung Lee; Gheeyoung Choe; Jin Haeng Chung; Woo Ho Kim
Journal:  Virchows Arch       Date:  2006-04-28       Impact factor: 4.064

Review 5.  Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms.

Authors:  Gaius J Augustus; Nathan A Ellis
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

6.  Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma.

Authors:  Chakrapani Chatla; Nirag C Jhala; Venkat R Katkoori; Dominik Alexander; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  Cancer Biomark       Date:  2005       Impact factor: 4.388

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  Differentiation pathways in duodenal and ampullary carcinomas: a comparative study on mucin and trefoil peptide expression, including gastric and colon carcinomas.

Authors:  Yesim Gürbüz; Günter Klöppel
Journal:  Virchows Arch       Date:  2004-04-08       Impact factor: 4.064

Review 9.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  Clinicopathological Significance of Mucin 2 Immuno-histochemical Expression in Colorectal Cancer: A Meta-Analysis.

Authors:  Li Li; Pei-Lin Huang; Xiao-Jin Yu; Xiao-Dong Bu
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.